Pol F. Boudes - 24 Jan 2024 Form 4 Insider Report for GALECTIN THERAPEUTICS INC (GALT)

Reporting relationship: Chief Medical Officer
Issuer ticker: GALT
Reported as of: 24 Jan 2024
Net transaction value: $0
SEC form: 4
Accepted by SEC: 07 Feb 2024, 16:43:19 UTC
Prior SEC filing: 03 Oct 2023
Next SEC filing: 04 Sep 2025
Source filing: View source filing
Reporting owner signature: Jack W. Callicutt, by power of attorney

Key filing fact

Pol F. Boudes filed Form 4 for GALECTIN THERAPEUTICS INC (GALT) on 07 Feb 2024.

Key facts

This page summarizes Pol F. Boudes's Form 4 filing for GALECTIN THERAPEUTICS INC (GALT).
2 reported transactions and 2 derivative rows are listed below.
Accepted by SEC: 07 Feb 2024, 16:43.

Change

Previous filing in this sequence was filed on 03 Oct 2023.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

GALT transaction Derivative

Stock Option (right to buy)

Award

Transaction value: $0
Shares: +65,000
Change %
Price: $0.000000
Shares after: 65,000
Date: 24 Jan 2024
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 65,000
Exercise price: $1.11
Footnotes: F1, F2

GALT transaction Derivative

Restricted Stock Unit

Award

Transaction value: $0
Shares: +40,000
Change %
Price: $0.000000
Shares after: 40,000
Date: 24 Jan 2024
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 40,000
Exercise price
Footnotes: F3, F4

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 4 footnotes

Footnote F1

The stock options were issued pursuant to the Galectin Therapeutics, Inc. 2019 Omnibus Equity Incentive Plan.

Footnote F2

The options vest as follows: 25% on each of June 30, 2023; December 31, 2023; June 30, 2024; and December 31, 2024.

Footnote F3

The Restricted Stock Units, if vested, convert into Common Stock on a one for one basis.

Footnote F4

Restricted Stock Units vest 100% upon public announcement of Interim Analysis data from NAVIGATE clinical trial if such announcement is made on or before December 31, 2024 or they will expire unvested.